Perspektywy immunoterapii chorób alergicznych I. Terapia przeciwciałami monoklonalnymi
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
paź 23, 2007
Słowa kluczowe:
immunoterapia, choroby alergiczne, przeciwciała monoklonalne
##plugins.themes.bootstrap3.article.main##
Abstrakt
W pracy przedstawiono aktualny stan wiedzy na temat użycia przeciwciał monoklonalnych w leczeniu chorób alergicznych. Na świecie przetestowano lub bada się kilkanaście przeciwciał monoklonalnych w alergologii: 1. neutralizujące cytokiny, w tym chemokiny (przeciwciała anty-IL-4, anty-IL-5, anty-IL-13, anty-TNF-α i przeciwko eotaksynie 1 – anty-CCL11), 2. blokujące receptory dla cytokin (przeciwciało anty- -IL-2R), 3. blokujące cząsteczki powierzchniowe komórek uczestniczących w zjawiskach nadwrażliwości typu I (przeciwciała anty-CD4, anty- -CD11a, anty-CD23) oraz 4. neutralizujące IgE (anty-IgE). Jak do tej pory tylko jedno przeciwciało monoklonalne – omalizumab – zarejestrowano w klinice w leczeniu alergii w terapii ciężkich postaci astmy.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Lasek , W. (2007). Perspektywy immunoterapii chorób alergicznych I. Terapia przeciwciałami monoklonalnymi. Alergoprofil, 3(3), 2-7. Pobrano z https://journalsmededu.pl/index.php/alergoprofil/article/view/17
Numer
Dział
Artykuł
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Berry M.A., Hargadon B., Shelley M. et al.: Evidence of a role of tumor necrosis factor α in refractory asthma. N. Engl. J. Med. 2006, 354: 697-708.
2. Blanchard C., Mishra A., Saito-Akei H. et al.: Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT354). Clin. Exp. Allergy 2005, 35: 1096-1103.
3. Chciałowski A., Lubiński W.: Rola cząsteczek adhezyjnych w procesie zapalnym obturacyjnych chorób płuc i możliwości jego kontroli. Alergoprofil 2005, 1(1): 11-18.
4. Erin E.M., Leaker B.R., Nicholson G.C. et. al. The effects of monoclonal antibody directed against tumor necrosis factor-α (TNF- α) in asthma. Am. J. Respir. Crit. Care Med. 2006, 174: 753-762.
5. Flood-Page P.T., Menzies-Gow A.N., Kay A.B., Robinson D.S.: Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care Med. 2003, 167: 199-204.
6. Gauvreau G.M., Becker A.B., Boulet L.P. et al.: The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J. Allergy Clin. Immunol. 2003, 112: 331-338.
7. Gevaert P., LangLoidolt D., Lackner A. et al.: Nasal IL-5 levels determine the response to anti-IL-5 treatment inpatients with nasal polyps. J. Allergy Clin. Immunol. 2006, 118: 1133-1141.
8. Holgate S.T.: Cytokine and anticytokine therapy for the treatment of asthma and allergic diseases. Alergol. International 2004, 5: 47-54.
9. Holgate S.T., Djukanović T., Casale T., Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin. Exp. Allergy 2005, 35: 408-416.
10. Jacobi A., Antoni C., Manger B. et al.: Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2005, 52: 522-526.
11. Kon O.M., Sihra B.S., Loh L.C. et al.: The effects of an antiCD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma. Eur. Respir. J. 2001, 18: 45-52.
12. Leckie M.J., ten Brinke A., Khan J. et al.: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthatic response. Lancet 2000, 356: 2144-2148.
13. Leung D.Y.M., Samson H.A., Yunginger J.W. et al.: Effect of anti-IgE therapy In patients with peanut allergy. N. Engl. J. Med. 2003, 348: 986-993.
14. Oldhoff J.M., Darsow U., Werfel T. et al.: No effect of antiinterleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients. Int. Arch. Allergy Immunol. 2006, 141: 290-294.
15. Poole J.A., Meng J., Reff M. et al.: Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J. Allergy Clin. Immunol. 2005, 116: 780-788.
16. Rogala B., Kasperska-Zając A.: Xolair w praktyce klinicznej. Alergia Astma Immunologia 2006; 11: 83-86.
17. Rosenberg H.F., Phipps S., Foster P.S.: Eosinophil trafficking in allergy and asthma. J. Allergy Clin. Immunol. 2007, 119: 1303-1310.
18. Rosenwasser L.J., Busse W.W., Lizambri R.G. et al.: Allergic asthma and an anti-CD23 mAb (IDEC-152): Results of a phase I, single-dose, dose-escalating clinical trial. J. Allergy Clin. Immunol. 2003, 112: 563-570.
19. Simon D., Braathen L.R., Simon H.U.: Anti-interleukin-5 antibody therapy in eosinophilic diseases. Pathobiology 2005, 72: 287-292.
20. Stein M.L., Villanueva J.M., Jameson S.C. et al.: Anti-IL5 therapy inhypereosinophilic syndromes and eosinophilic esophagitis: cytokine secretion and decrease peripheral blood eosinophilia (abstract). J. Allergy Clin. Immunol. 2006, 117: S58.
21. Toda M., Nakamura T., Ohbayashi M. et al.: Mechanisms of leukocyte trafficking in allergic diseases: insight into new therapies targeting chemokine an chemokine receptors. Expert Rev. Clin. Immunol. 2007, 3: 351-364.
22. Tsitoura D.C., Tassios Y.: Immunomodulation. The future cure for allergic diseases. Ann. N.Y. Acad. Sci. 2006, 1088: 100-115.
23. Weller P.F., Gleich G.J., Busse W.W., Rothenberg M.E.: Effects of mepolizumab, an anti-interleukin-5 monoclonal antibody, on blood eosinophiol counts in patients with hypereosinophilic syndrome (abstract). J. Allergy Clin. Immunol. 2007, 119: S209.
24. Online: http://clinicaltrials.gov/ct/show/NCT00028288 (Access: 16.07.2007) .
25. Online: http://clinicaltrials.gov/show/NCT00358449 (Access: 16.07.2007) .
26. Online: http://clinicaltrials.gov/ct/show/NCT00024544 (Access: 16.07.2007) .
27. Online: http://clinicaltrials.gov/ct/show/NCT00394654 (Access: 16.07.2007).
28. Online: http://www.cambridgeantibody.com/home/news_and_resources/news_releases/2006 22 May 2006 (Access: 16.07.2007) .
29. Online: http://www.icotherapeutics.com/site/news_media/press_releases …8 January 2007 (Access: 16.07.2007).
30. Online: http://allergy.immunodefence.com/2006/10/ …27 October 2006 (Access: 16.07.2007).
31. Online: http://www.xolair.pl (Access: 16.07.2007) .
2. Blanchard C., Mishra A., Saito-Akei H. et al.: Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT354). Clin. Exp. Allergy 2005, 35: 1096-1103.
3. Chciałowski A., Lubiński W.: Rola cząsteczek adhezyjnych w procesie zapalnym obturacyjnych chorób płuc i możliwości jego kontroli. Alergoprofil 2005, 1(1): 11-18.
4. Erin E.M., Leaker B.R., Nicholson G.C. et. al. The effects of monoclonal antibody directed against tumor necrosis factor-α (TNF- α) in asthma. Am. J. Respir. Crit. Care Med. 2006, 174: 753-762.
5. Flood-Page P.T., Menzies-Gow A.N., Kay A.B., Robinson D.S.: Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care Med. 2003, 167: 199-204.
6. Gauvreau G.M., Becker A.B., Boulet L.P. et al.: The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J. Allergy Clin. Immunol. 2003, 112: 331-338.
7. Gevaert P., LangLoidolt D., Lackner A. et al.: Nasal IL-5 levels determine the response to anti-IL-5 treatment inpatients with nasal polyps. J. Allergy Clin. Immunol. 2006, 118: 1133-1141.
8. Holgate S.T.: Cytokine and anticytokine therapy for the treatment of asthma and allergic diseases. Alergol. International 2004, 5: 47-54.
9. Holgate S.T., Djukanović T., Casale T., Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin. Exp. Allergy 2005, 35: 408-416.
10. Jacobi A., Antoni C., Manger B. et al.: Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2005, 52: 522-526.
11. Kon O.M., Sihra B.S., Loh L.C. et al.: The effects of an antiCD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma. Eur. Respir. J. 2001, 18: 45-52.
12. Leckie M.J., ten Brinke A., Khan J. et al.: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthatic response. Lancet 2000, 356: 2144-2148.
13. Leung D.Y.M., Samson H.A., Yunginger J.W. et al.: Effect of anti-IgE therapy In patients with peanut allergy. N. Engl. J. Med. 2003, 348: 986-993.
14. Oldhoff J.M., Darsow U., Werfel T. et al.: No effect of antiinterleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients. Int. Arch. Allergy Immunol. 2006, 141: 290-294.
15. Poole J.A., Meng J., Reff M. et al.: Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J. Allergy Clin. Immunol. 2005, 116: 780-788.
16. Rogala B., Kasperska-Zając A.: Xolair w praktyce klinicznej. Alergia Astma Immunologia 2006; 11: 83-86.
17. Rosenberg H.F., Phipps S., Foster P.S.: Eosinophil trafficking in allergy and asthma. J. Allergy Clin. Immunol. 2007, 119: 1303-1310.
18. Rosenwasser L.J., Busse W.W., Lizambri R.G. et al.: Allergic asthma and an anti-CD23 mAb (IDEC-152): Results of a phase I, single-dose, dose-escalating clinical trial. J. Allergy Clin. Immunol. 2003, 112: 563-570.
19. Simon D., Braathen L.R., Simon H.U.: Anti-interleukin-5 antibody therapy in eosinophilic diseases. Pathobiology 2005, 72: 287-292.
20. Stein M.L., Villanueva J.M., Jameson S.C. et al.: Anti-IL5 therapy inhypereosinophilic syndromes and eosinophilic esophagitis: cytokine secretion and decrease peripheral blood eosinophilia (abstract). J. Allergy Clin. Immunol. 2006, 117: S58.
21. Toda M., Nakamura T., Ohbayashi M. et al.: Mechanisms of leukocyte trafficking in allergic diseases: insight into new therapies targeting chemokine an chemokine receptors. Expert Rev. Clin. Immunol. 2007, 3: 351-364.
22. Tsitoura D.C., Tassios Y.: Immunomodulation. The future cure for allergic diseases. Ann. N.Y. Acad. Sci. 2006, 1088: 100-115.
23. Weller P.F., Gleich G.J., Busse W.W., Rothenberg M.E.: Effects of mepolizumab, an anti-interleukin-5 monoclonal antibody, on blood eosinophiol counts in patients with hypereosinophilic syndrome (abstract). J. Allergy Clin. Immunol. 2007, 119: S209.
24. Online: http://clinicaltrials.gov/ct/show/NCT00028288 (Access: 16.07.2007) .
25. Online: http://clinicaltrials.gov/show/NCT00358449 (Access: 16.07.2007) .
26. Online: http://clinicaltrials.gov/ct/show/NCT00024544 (Access: 16.07.2007) .
27. Online: http://clinicaltrials.gov/ct/show/NCT00394654 (Access: 16.07.2007).
28. Online: http://www.cambridgeantibody.com/home/news_and_resources/news_releases/2006 22 May 2006 (Access: 16.07.2007) .
29. Online: http://www.icotherapeutics.com/site/news_media/press_releases …8 January 2007 (Access: 16.07.2007).
30. Online: http://allergy.immunodefence.com/2006/10/ …27 October 2006 (Access: 16.07.2007).
31. Online: http://www.xolair.pl (Access: 16.07.2007) .